In addition to the genetic HIPK1 ablation in mice, we also applied cTnT‐sh‐HIPK1‐AAV9 treatment in TAC animal model, and found that gene therapy that reduced HIPK1 in the heart had similar protective effects against pathological cardiac hypertrophy, as indicated by reduced myocardial hypertrophy, cardiac fibrosis, and cardiac dysfunction. The gene discussed is TNNT2; the disease is persistent truncus arteriosus.